{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:16:17Z","timestamp":1764936977149,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.clml.2018.02.017","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T19:17:56Z","timestamp":1520018276000},"page":"346-352.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["A Phase I\/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia"],"prefix":"10.1016","volume":"18","author":[{"given":"Bruno C.","family":"Medeiros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7656-5249","authenticated-orcid":false,"given":"Tiffany N.","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larisa","family":"Balaian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asad","family":"Bashey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Guzdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Messer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward D.","family":"Ball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.02.017_bib1","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","article-title":"Acute myeloid leukemia","volume":"341","author":"L\u00f6wenberg","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.02.017_bib2","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V88.2.756.bloodjournal882756","article-title":"A\u00a0stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia","volume":"88","author":"Estey","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.017_bib3","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/sj.leu.2401663","article-title":"Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate","volume":"14","author":"Bernstein","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.017_bib4","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1200\/JCO.2001.19.13.3244","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse","volume":"19","author":"Sievers","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.017_bib5","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A\u00a0phase 3 study of gemtuzumab ozogamycin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.017_bib6","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2018.02.017_bib7","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukemia: a meta-analysis of individual patient data from randomized controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.02.017_bib8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.leukres.2014.11.009","article-title":"Azacitidine for the treatment of relapsed and refractory AML in older patients","volume":"39","author":"Itzykson","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2018.02.017_bib9","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1200\/JCO.2006.09.4169","article-title":"Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia","volume":"25","author":"Blum","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.02.017_bib10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/ajh.23464","article-title":"5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy","volume":"88","author":"Ivanoff","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.02.017_bib11","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2015-11-680546","article-title":"Decitabine enhances Fc engineered anti-CD33 mAb mediated natural killer antibody dependent cellular cytotoxicity against AML blasts","volume":"127","author":"Vasu","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.017_bib12","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1182\/blood-2013-06-506592","article-title":"A\u00a0phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia","volume":"122","author":"Nand","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.017_bib13","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood.V98.4.988","article-title":"Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin","volume":"98","author":"Linenberger","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.017_bib14","first-page":"116","article-title":"Update of a phase I\/II trial of 5-azacytidine prior to gemtuzumab ozogamicin (GO) for patients with relapsed acute myeloid leukemia with correlative biomarker studies","author":"Ball","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.017_bib15","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/sj.leu.2404437","article-title":"Cytotoxic activity of gemtuzumab ozogamycin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk","volume":"20","author":"Balaian","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.017_bib16","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2307\/2531693","article-title":"Design and analysis of phase I clinical trials","volume":"45","author":"Storer","year":"1989","journal-title":"Biometrics"},{"key":"10.1016\/j.clml.2018.02.017_bib17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.02.017_bib18","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.21326","article-title":"Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence","volume":"104","author":"Larson","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.02.017_bib19","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/leu.2015.244","article-title":"A\u00a0phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"30","author":"Daver","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.02.017_bib20","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3324\/haematol.2016.141937","article-title":"Defining the dose of gemtuzumab ozogamycin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg\/m2 with 6 mg\/m2 in the NCRI AML17 trial","volume":"101","author":"Burnett","year":"2016","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018300594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018300594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:19Z","timestamp":1761870619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018300594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S2152265018300594"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.02.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase I\/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}